Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients. / Fang, Chao; Fang, Wenfeng; Xu, Liqin; Gao, Fangfang; Hou, Yong; Zou, Hua; Ma, Yuxiang; Moll, Janne Marie; Yang, Yunpeng; Wang, Dan; Huang, Yan; Ren, Huahui; Zhao, Hongyun; Qin, Shishang; Zhong, Huanzi; Li, Junhua; Liu, Sheng; Yang, Huanming; Wang, Jian; Brix, Susanne; Kristiansen, Karsten; Zhang, Li.
In: Frontiers in Oncology, Vol. 12, 837525, 2022.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer Patients
AU - Fang, Chao
AU - Fang, Wenfeng
AU - Xu, Liqin
AU - Gao, Fangfang
AU - Hou, Yong
AU - Zou, Hua
AU - Ma, Yuxiang
AU - Moll, Janne Marie
AU - Yang, Yunpeng
AU - Wang, Dan
AU - Huang, Yan
AU - Ren, Huahui
AU - Zhao, Hongyun
AU - Qin, Shishang
AU - Zhong, Huanzi
AU - Li, Junhua
AU - Liu, Sheng
AU - Yang, Huanming
AU - Wang, Jian
AU - Brix, Susanne
AU - Kristiansen, Karsten
AU - Zhang, Li
N1 - Publisher Copyright: Copyright © 2022 Fang, Fang, Xu, Gao, Hou, Zou, Ma, Moll, Yang, Wang, Huang, Ren, Zhao, Qin, Zhong, Li, Liu, Yang, Wang, Brix, Kristiansen and Zhang.
PY - 2022
Y1 - 2022
N2 - Background: Programmed death 1 (PD-1) and the ligand of PD-1 (PD-L1) are central targets for immune-checkpoint therapy (ICT) blocking immune evasion-related pathways elicited by tumor cells. A number of PD-1 inhibitors have been developed, but the efficacy of these inhibitors varies considerably and is typically below 50%. The efficacy of ICT has been shown to be dependent on the gut microbiota, and experiments using mouse models have even demonstrated that modulation of the gut microbiota may improve efficacy of ICT. Methods: We followed a Han Chinese cohort of 85 advanced non-small cell lung cancer (NSCLC) patients, who received anti-PD-1 antibodies. Tumor biopsies were collected before treatment initiation for whole exon sequencing and variant detection. Fecal samples collected biweekly during the period of anti-PD-1 antibody administration were used for metagenomic sequencing. We established gut microbiome abundance profiles for identification of significant associations between specific microbial taxa, potential functionality, and treatment responses. A prediction model based on random forest was trained using selected markers discriminating between the different response groups. Results: NSCLC patients treated with antibiotics exhibited the shortest survival time. Low level of tumor-mutation burden and high expression level of HLA-E significantly reduced progression-free survival. We identified metagenomic species and functional pathways that differed in abundance in relation to responses to ICT. Data on differential enrichment of taxa and predicted microbial functions in NSCLC patients responding or non-responding to ICT allowed the establishment of random forest algorithm-adopted models robustly predicting the probability of whether or not a given patient would benefit from ICT. Conclusions: Overall, our results identified links between gut microbial composition and immunotherapy efficacy in Chinese NSCLC patients indicating the potential for such analyses to predict outcome prior to ICT.
AB - Background: Programmed death 1 (PD-1) and the ligand of PD-1 (PD-L1) are central targets for immune-checkpoint therapy (ICT) blocking immune evasion-related pathways elicited by tumor cells. A number of PD-1 inhibitors have been developed, but the efficacy of these inhibitors varies considerably and is typically below 50%. The efficacy of ICT has been shown to be dependent on the gut microbiota, and experiments using mouse models have even demonstrated that modulation of the gut microbiota may improve efficacy of ICT. Methods: We followed a Han Chinese cohort of 85 advanced non-small cell lung cancer (NSCLC) patients, who received anti-PD-1 antibodies. Tumor biopsies were collected before treatment initiation for whole exon sequencing and variant detection. Fecal samples collected biweekly during the period of anti-PD-1 antibody administration were used for metagenomic sequencing. We established gut microbiome abundance profiles for identification of significant associations between specific microbial taxa, potential functionality, and treatment responses. A prediction model based on random forest was trained using selected markers discriminating between the different response groups. Results: NSCLC patients treated with antibiotics exhibited the shortest survival time. Low level of tumor-mutation burden and high expression level of HLA-E significantly reduced progression-free survival. We identified metagenomic species and functional pathways that differed in abundance in relation to responses to ICT. Data on differential enrichment of taxa and predicted microbial functions in NSCLC patients responding or non-responding to ICT allowed the establishment of random forest algorithm-adopted models robustly predicting the probability of whether or not a given patient would benefit from ICT. Conclusions: Overall, our results identified links between gut microbial composition and immunotherapy efficacy in Chinese NSCLC patients indicating the potential for such analyses to predict outcome prior to ICT.
KW - anti-PD-1
KW - biomarker
KW - gut microbiome
KW - immune checkpoint therapy
KW - lung cancer
U2 - 10.3389/fonc.2022.837525
DO - 10.3389/fonc.2022.837525
M3 - Journal article
C2 - 35530307
AN - SCOPUS:85129672667
VL - 12
JO - Frontiers in Oncology
JF - Frontiers in Oncology
SN - 2234-943X
M1 - 837525
ER -
ID: 310388491